Re: Millenium Phamaceuticals - How high will it go?

The pot, as we see it, is still 90% empty. The good thing in this domain of technology is that the capacity is not all in one pot but in several pots that can be filled one after the other. The best speculators cannot speculatre on the number of empty pts. Amgen has filled seven or eight of them, until now and is in the middle of filling another one. If old enough, you must then certainly know the saying " eye sight has limits. Insight doesn't. As complex as it is the anatomy of the eye, that of insight is several fold more complex. Trying to understand the components of the eye won't hurt. Trying to do the same with insight one would lose it. MLNM, our instinct tells us, has a long, long way to go. It will prove that it is, indeed, the Jewel of the drug discovery ulta-modern process and will fill several pots like the one that some people think it is full.

Please Note: This discussion is open to all site visitors and is not regulated by Prohost. Information posted in the discussion should not be considered to be coming from Prohost Research.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm.

Send mail to CompanyWebmaster with questions or comments about this web site.
Copyright © 2001 CompanyLongName
Last modified: October 14, 2003

AVN / expect ''meteoric bull market ...''

Comments

AVN / expect ''meteoric bull market ...'' Amex stocks poised for explosive summer rally "..Avanir Pharmaceuticals (AVN) is a prime example of what happens when the lines of supply that have suppressed a stock’s price are finally overcome (viz., its trendlines get broken). After a one-year downward trend, AVN moved higher last week in explosive fashion, which we believe is a harbinger of what many other stocks across the board will experience later this spring. You can expect a pullback (or at least a consolidative rest) in AVN sometime in the next few days. However, AVN must be considered a technical buy candidate and not just a one-hit wonder. If AVN overcomes $9 ultimate resistance, expect a meteoric bull market this summer in this stock. " --Clif Droke iStockForecast.com also remember... AVN institutional ownership has practically quadrupled in a short period of time. The big boys seem content in gradually accumulating the shares from retail shareholders who continue to hold on tight. One can only imagine how successful AVN will be if institutional ownership continues to grow as large as it's nearest competitor MEDX with 60%. With still only 3.2%, it seems AVN has rocketship potential considering that they feel their Xenerex technology is better than MEDX and they have the first OTC FDA approved herpes cream being marketed successfully as "Abreva" through Glaxo SmithKline. AVN Could Be the New Mab Leader Interesting news in the biotech world has arrived. Eos has signed the first partnership with AVN's Xenerex which will compete with MEDX, ABGX and PDLI in making fully human monoclonal antibodies. What's even more interesting is that Eos' chairman of the board is Nicholas Pritzker and a major investor in Eos is the Pritker Family's BCC bank. The Pritzkers are the multibillionairs of Hyatt Hotel fame who were instumental is the growth of MEDX. The Pritzkers through BCC were one of MEDX's largest investors. Immediately after the deal with AVN, Eos announced that they were retuning $5M to MEDX which was in the terms of an already existing deal. One has to assume that the terms of the contract being changed were in connection with the AVN/Xenerex deal. Why would the Pritzkers lean towards AVN/Xenerex now? Perhaps this has something to do with it... "Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human antibodies faster and cheaper than its competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody Technology plc, Hansen said. " Bioworld Online, Aug 21, 2000

Prohost Biotechnology Online

The Newsletter of Biotechnology Research and Investment

P R O H O S T O n l i n e
The Newsletter of Biotechnology Insight and Investment

Biotechnology Discussion